Pharmaciens et Institut national du cancer : Partenaires pour la mise en oeuvre du Plan Cancer. 19e Journée de l'Ordre, Paris le 9 novembre 2006, Bulletin de l'ordre des pharmaciens, vol.393, pp.421-429, 2006. ,
relative à la mise en oeuvre du contrat de bon usage des médicaments et produits et prestations mentionné à l'article L, pp.162-184, 2006. ,
Présentation générale des OMEDITs, Réunion APHNEP, 2007. ,
Imputabilité des effets inattendus ou toxiques des médicaments, Thérapie, vol.40, pp.111-119, 1985. ,
Does rituximab increase the incidence of infectious complications? A narrative review, International Journal of Infectious Diseases, vol.15, issue.1, pp.2-16, 2011. ,
DOI : 10.1016/j.ijid.2010.03.025
A review of the current use of rituximab in autoimmune diseases, International Immunopharmacology, vol.9, issue.1, pp.10-25, 2009. ,
DOI : 10.1016/j.intimp.2008.10.004
A Systematic Review of the Off-Label Use of Biological Therapies in Systemic Autoimmune Diseases, Medicine, vol.87, issue.6, pp.345-364, 2008. ,
DOI : 10.1097/MD.0b013e318190f170
Effectiveness and side effects of anti-CD20 therapy for autoantibodymediated blistering skin diseases: A comprehensive survey of 71consecutive patients from the Initial use to, Therapeutics and Clinical Risk Management, vol.5, pp.1-7, 2007. ,
Rituximab in Severe Pemphigus, Annals of the New York Academy of Sciences, vol.30, issue.Suppl 1, pp.683-691, 2009. ,
DOI : 10.1111/j.1749-6632.2009.04744.x
The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases, British Journal of Haematology, vol.60, issue.Suppl 2, pp.3-13, 2010. ,
DOI : 10.1111/j.1365-2141.2010.08076.x
CD20-directed therapy in autoimmune diseases involving the skin: role of rituximab, Expert Review of Dermatology, vol.3, issue.3, pp.259-278, 2008. ,
DOI : 10.1586/17469872.3.3.259
The effects of rituximab on immunocompetency in patients with autoimmune disease, Arthritis & Rheumatism, vol.3, issue.1, pp.5-14, 2008. ,
DOI : 10.1002/art.23171
Rituximab off-label use for immune diseases: assessing adverse events in a single-centre drug-utilization survey, British Journal of Clinical Pharmacology, vol.47, issue.2, pp.320-322, 2008. ,
DOI : 10.1111/j.1365-2125.2008.03193.x
B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis, Arthritis & Rheumatism, vol.56, issue.2, pp.578-583, 2009. ,
DOI : 10.1002/art.24249
Rituximab in Severe Lupus Nephritis: Early B-Cell Depletion Affects Long-Term Renal Outcome, Clinical Journal of the American Society of Nephrology, vol.4, issue.3, pp.579-587, 2009. ,
DOI : 10.2215/CJN.04030808
Treatment of treatment-resistant autoimmune blistering skin disorders with rituximab, British Journal of Dermatology, vol.128, issue.6, pp.1335-1362, 2009. ,
DOI : 10.1111/j.1365-2133.2009.09132.x
B-cell depletion with rituximab for refractory head and neck Wegener???s granulomatosis: a cohort study, Clinical Otolaryngology, vol.22, issue.4 ,
DOI : 10.1111/j.1749-4486.2009.01968.x
Effective rituximab treatment in primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled trial, 2010. ,
Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus, Nephrology Dialysis Transplantation, vol.25, issue.11, pp.1-7, 2010. ,
DOI : 10.1093/ndt/gfq256
Rituximab as Maintenance Therapy for ,
Combe et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AIR registry ,